Benzinga's Microcap Movers for Tuesday September 18, 2012
Below are highlights from Benzinga's daily coverage of small cap and microcap securities making big moves:
Shares of Emisphere Technologies (OTC: EMIS), the Cedar Knolls, NJ biopharmaceutical company, rose 129% Tuesday on 10 times average volume.
On September 17, 2012, Emisphere Technologies announced that Alan L. Rubino has been appointed to the position of President and Chief Executive Officer of the Company, effective September 13, 2012. Pursuant to his appointment, Mr. Rubino entered into an Employment Agreement with the Company dated September 13, 2012.
The effective date of the Employment Agreement is September 13, 2012. The initial term of the Employment Agreement is three years, and the agreement will automatically renew for additional one-year terms unless either party provides notice of non-renewal to the other party at least six months prior to the end of the initial term or any renewal terms.
Emisphere Technologies closed at $0.21 on Tuesday.
United Treatment Centers
Shares of United Treatment Centers (OTC: UTRM), the Port Washington, NY oral health care company, rose 566% Tuesday on 110 million shares.
Element Trading Technologies has completed a reverse merger into United Treatment Centers. Element Trading Technologies will be filing with FINRA for a company name change and new trading symbol.
Emisphere Technologies closed at $0.0021 on Tuesday.
China-Biotics (OTC: CHBT), the China-based dietary supplement company, rose 78.95% Tuesday on 9 times average volume.
There was no news to account for the move in China-Biotics Tuesday. A company spokesperson was not available for comment.
China-Biotics float is 45% short.
China-Biotics closed at $3.40 on Tuesday.
The information in this article is taken from public sources, press releases, and websites that cannot always be verified. Please note that investing in microcap stocks is highly speculative. The companies mentioned here are for information purposes only. Benzinga makes no claim as to the suitability of these stocks as an investment. Neither Benzinga nor its staff recommend that you buy, sell, or hold any security. We do not offer investment advice, personalized or otherwise. Benzinga recommends that you conduct your own due diligence and consult a certified financial professional for personalized advice about your financial situation.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.